AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 343062 — intervention group
Group type: EXPERIMENTAL
Intervention: Large muscle exercise
Number of subjects: 0
Study 343062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhyperactive control
Number of subjects: 0
Study 343062 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study 343062 — intervention group
Group type: COMPARATOR
Intervention: Attentional-training placebo
Number of subjects: 0
Study 31858264 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 40
Study 31858264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 40
Study 31858264 — intervention group
Group type: COMPARATOR
Intervention: Group cognitive-behavioral therapy (CBT) or sertraline
Number of subjects: 40
Study 30997411 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider and patient education and provider feedback via biweekly, unblinded normative comparison
Number of subjects: 192
Study 30997411 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 192
Study 28284655 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and text instructions for eyelid laceration repair
Number of subjects: 16
Study 28284655 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and text instructions for blepharoplasty
Number of subjects: 16
Study 28284655 — intervention group
Group type: COMPARATOR
Intervention: Text instructions alone for eyelid laceration repair
Number of subjects: 16
Study 28284655 — intervention group
Group type: COMPARATOR
Intervention: Text instructions alone for blepharoplasty
Number of subjects: 16
Study 25517204 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg mirtazapine daily for 8 weeks
Number of subjects: 59
Study 25517204 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 59
Study 23352604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus XELIRI (irinotecan 200mg/m² on day 1 and oral capecitabine 1,000 mg/m² bid on days 1-14)
Number of subjects: 145
Study 23352604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFIRI (5-fluorouracil 400mg/m² on day 1 plus 2,400 mg/m² as a 46-h infusion, leucovorin 400mg/m² on day 1, and irinotecan 180 mg/m² on day 1)
Number of subjects: 145
Study 23352604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 145
Study 23352604 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab-XELIRI
Number of subjects: 145
Study 23352604 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab-FOLFIRI
Number of subjects: 145
Study 21205360 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplementation (1000 mg Ca/d)
Number of subjects: 25
Study 21205360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isoenergetic)
Number of subjects: 25
Study 19278785 — intervention group
Group type: EXPERIMENTAL
Intervention: Social observation (Group 1)
Number of subjects: 3
Study 19278785 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning procedure (Group 2)
Number of subjects: 3
Study 19278785 — intervention group
Group type: COMPARATOR
Intervention: Verbal suggestion (Group 3)
Number of subjects: 3
Study 18046223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg
Number of subjects: 97
Study 18046223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg and intravitreal triamcinolone (IVT) 2 mg
Number of subjects: 97
Study 18046223 — intervention group
Group type: COMPARATOR
Intervention: Macular photocoagulation (MPC)
Number of subjects: 97
Study 15522365 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 336
Study 15522365 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 336
Study 15522365 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (for patients with baseline VA > 20/200)
Number of subjects: 336
Study 15522365 — intervention group
Group type: COMPARATOR
Intervention: Observation (for patients with baseline VA > 20/200)
Number of subjects: 336
Study 11403365 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of male gender
Number of subjects: 18790
Study 11403365 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > or = 65 years
Number of subjects: 18790
Study 11403365 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 18790
Study 11403365 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum cholesterol (> 6.8 mmol/l)
Number of subjects: 18790
Study 11403365 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum creatinine (> 155 micromol/l)
Number of subjects: 18790
Study 11403365 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 18790
Study 11403365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic heart disease
Number of subjects: 18790
Study 9814867 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine
Number of subjects: 1488
Study 9814867 — intervention group
Group type: COMPARATOR
Intervention: Control treatments
Number of subjects: 1488
Study 7877124 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 37
Study 3358819 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention (mean serum ethanol concentration 93 mg/100 ml, S.D. 17)
Number of subjects: 30
Study 3358819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alcohol)
Number of subjects: 30
Study 31539362 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength training (HBST)
Number of subjects: 32
Study 31539362 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 32
Study 28431952 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative patient education video
Number of subjects: 100
Study 28431952 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 28431952 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient perception of time spent with health care team
Number of subjects: 100
Study 28431952 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual time spent with health care team
Number of subjects: 100
Study 28431952 — intervention group
Group type: EXPERIMENTAL
Intervention: History of previous surgery
Number of subjects: 100
Study 28431952 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of apical prolapse
Number of subjects: 100
Study 25931141 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine (LY IGlar)
Number of subjects: 756
Study 25931141 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 756
Study 24043733 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily manual lymphatic drainage and bandaging followed by compression garments
Number of subjects: 95
Study 24043733 — intervention group
Group type: COMPARATOR
Intervention: Compression garments
Number of subjects: 95
Study 21762907 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 142
Study 21762907 — intervention group
Group type: EXPERIMENTAL
Intervention: I-Scan
Number of subjects: 142
Study 21762907 — intervention group
Group type: COMPARATOR
Intervention: High-definition white-light colonoscopy
Number of subjects: 142
Study 19500091 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Clinical Intervention (ECI) + Specialized Care for Bipolar Disorder (SCBD)
Number of subjects: 463
Study 19500091 — intervention group
Group type: COMPARATOR
Intervention: Specialized Care for Bipolar Disorder (SCBD)
Number of subjects: 463
Study 16458700 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg nimesulide
Number of subjects: 16
Study 16458700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15268833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile ocular blood flow (POBF) measurement in POAG patients
Number of subjects: 100
Study 15268833 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile ocular blood flow (POBF) measurement in normal control group
Number of subjects: 100
Study 15268833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of POBF for diagnosis of POAG
Number of subjects: 100
Study 15268833 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between changes of visual field and POBF
Number of subjects: 100
Study 11405809 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan malate, 12.5 mg
Number of subjects: 1173
Study 11405809 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan succinate, 50 mg
Number of subjects: 1173
Study 9565006 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 10172 (danaparoid sodium)
Number of subjects: 1281
Study 9565006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1281
Study 7997377 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐IBZM SPECT
Number of subjects: 58
Study 3057120 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (with and without nitrous oxide) at 0.5 MAC
Number of subjects: 104
Study 3057120 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (with and without nitrous oxide) at 1.0 MAC
Number of subjects: 104
Study 3057120 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (with and without nitrous oxide) at 1.5 MAC
Number of subjects: 104
Study 3057120 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 0.5 MAC
Number of subjects: 104
Study 3057120 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 1.0 MAC
Number of subjects: 104
Study 3057120 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at 1.5 MAC
Number of subjects: 104
Study 31965678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional methotrexate (MTX) 2 mg/ml
Number of subjects: 60
Study 31965678 — intervention group
Group type: COMPARATOR
Intervention: Intralesional saline (placebo)
Number of subjects: 60
Study 30311037 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drain
Number of subjects: 161
Study 30311037 — intervention group
Group type: COMPARATOR
Intervention: No closed suction drain
Number of subjects: 161
Study 26982627 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 52
Study 26982627 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 52
Study 25313848 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfortified mother's own milk (MOM)
Number of subjects: 25
Study 25313848 — intervention group
Group type: COMPARATOR
Intervention: S‐26 fortified mother's own milk (MOM)
Number of subjects: 25
Study 25313848 — intervention group
Group type: COMPARATOR
Intervention: FM 85 fortified mother's own milk (MOM)
Number of subjects: 25
Study 25313848 — intervention group
Group type: COMPARATOR
Intervention: 2-hourly feeds
Number of subjects: 25
Study 25313848 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 25
Study 23389497 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 additional doses of L-asparaginase (6000 IU/m2/dose) during consolidation treatment (3A arm)
Number of subjects: 117
Study 23389497 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without additional doses of L-asparaginase (0A arm)
Number of subjects: 117
Study 22187762 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 60
Study 22187762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 60
Study 22187762 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 60
Study 19892856 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 154
Study 19892856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (detuned ultrasound therapy and detuned short‐wave therapy)
Number of subjects: 154
Study 16564394 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 29
Study 16564394 — intervention group
Group type: COMPARATOR
Intervention: No earplugs
Number of subjects: 29
Study 15328092 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate 2,000/125 mg
Number of subjects: 633
Study 15328092 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate 875/125 mg
Number of subjects: 633
Study 12925082 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse coloplasty pouch (TCP)
Number of subjects: 30
Study 12925082 — intervention group
Group type: COMPARATOR
Intervention: Colonic J-pouch (CJP)
Number of subjects: 30
Study 12925082 — intervention group
Group type: COMPARATOR
Intervention: Transverse coloplasty pouch (TCP) and Colonic J-pouch (CJP)
Number of subjects: 30
Study 10780133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother present
Number of subjects: 64
Study 10780133 — intervention group
Group type: EXPERIMENTAL
Intervention: Blanket present
Number of subjects: 64
Study 10780133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother plus blanket present
Number of subjects: 64
Study 10780133 — intervention group
Group type: COMPARATOR
Intervention: No supportive agent
Number of subjects: 64
Study 8622502 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 2687
Study 8622502 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen or chemoendocrine therapy
Number of subjects: 2687
Study 8622502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic treatment
Number of subjects: 2687
Study 8622502 — intervention group
Group type: EXPERIMENTAL
Intervention: Later cytotoxic therapy
Number of subjects: 2687
Study 8622502 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipation of future therapy
Number of subjects: 2687
Study 8622502 — intervention group
Group type: COMPARATOR
Intervention: Oestrogen-receptor-negative tumours
Number of subjects: 2687
Study 8622502 — intervention group
Group type: COMPARATOR
Intervention: Number of involved axillary nodes
Number of subjects: 2687
Study 1442685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 14
Study 1442685 — intervention group
Group type: COMPARATOR
Intervention: Control (no cisapride)
Number of subjects: 14
Study 4076841 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol
Number of subjects: 50
Study 4076841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3119288 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel and Ethinylestradiol in tablet form (150/30)
Number of subjects: 9
Study 3119288 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel and Ethinylestradiol in capsule form
Number of subjects: 9
Study 31699127 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilson's disease patients (n=61)
Number of subjects: 61
Study 31699127 — intervention group
Group type: COMPARATOR
Intervention: Healthy control patients (n=61)
Number of subjects: 61
Study 27169431 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 27169431 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 0
Study 27169431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25589424 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 154
Study 25589424 — intervention group
Group type: COMPARATOR
Intervention: TVT-Secur
Number of subjects: 154
Study 25589424 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 23043722 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced feeding protocol
Number of subjects: 50
Study 23043722 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding protocol
Number of subjects: 50
Study 21798122 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based intervention (mailed printed materials)
Number of subjects: 276
Study 21798122 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 276
Study 19199221 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion Control Shoe (MC)
Number of subjects: 14
Study 19199221 — intervention group
Group type: COMPARATOR
Intervention: Cushioning Shoe (CU)
Number of subjects: 14
Study 16891382 — intervention group
Group type: COMPARATOR
Intervention: 3-month weight-loss (vs. weight-stability) in AMI patients (OPTIMAAL trial)
Number of subjects: 4360
Study 16891382 — intervention group
Group type: COMPARATOR
Intervention: 3-month weight-loss in AMI patients (CONSENSUS II trial)
Number of subjects: 4360
Study 16891382 — intervention group
Group type: COMPARATOR
Intervention: 1-year weight-loss in stable CAD patients (4S trial)
Number of subjects: 4360
Study 16891382 — intervention group
Group type: COMPARATOR
Intervention: Weight-gain in AMI patients (OPTIMAAL trial)
Number of subjects: 4360
Study 16891382 — intervention group
Group type: COMPARATOR
Intervention: Weight-gain in AMI patients (CONSENSUS II trial)
Number of subjects: 4360
Study 16891382 — intervention group
Group type: COMPARATOR
Intervention: Weight-gain in stable CAD patients (4S trial)
Number of subjects: 4360
Study 14982548 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus CM with an expected maximum of $240 of reinforcement
Number of subjects: 120
Study 14982548 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus CM with an expected maximum of $80 of reinforcement
Number of subjects: 120
Study 14982548 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 120
Study 11709606 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy including sulphasalazine (SSZ; 2000 mg/day), methotrexate (MTX; 7.5 mg/week), and prednisolone (initially 60 mg/day, tapered to 7.5 mg/day)
Number of subjects: 155
Study 11709606 — intervention group
Group type: COMPARATOR
Intervention: SSZ alone
Number of subjects: 155
Study 9385898 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-facilitated PTCA
Number of subjects: 215
Study 9385898 — intervention group
Group type: COMPARATOR
Intervention: Stand-alone PTCA
Number of subjects: 215
Study 8196493 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRH (100 ug i.v.)
Number of subjects: 10
Study 8196493 — intervention group
Group type: EXPERIMENTAL
Intervention: oCRH (100 ug i.v.)
Number of subjects: 10
Study 8196493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3367455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir, 400 mg five times daily
Number of subjects: 29
Study 3367455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30380017 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception lifestyle intervention targeting physical activity, diet, and behavior modification
Number of subjects: 150
Study 30380017 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 150
Study 28350210 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 87
Study 28350210 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 87
Study 26163901 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA)
Number of subjects: 294
Study 26163901 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 294
Study 26163901 — intervention group
Group type: COMPARATOR
Intervention: Crossover group
Number of subjects: 294
Study 26163901 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life improvement
Number of subjects: 294
Study 26163901 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 294
Study 24830913 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting intervention by staff nurses during routine primary care visits
Number of subjects: 184
Study 24830913 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 184
Study 22005905 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of 0.5% hyperbaric bupivacaine (Group I)
Number of subjects: 50
Study 22005905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of 0.5% hyperbaric bupivacaine combined with 2.5 μg sufentanil (Group II)
Number of subjects: 50
Study 19272667 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated home care and discharge practice (IHCaD‐practice)
Number of subjects: 668
Study 19272667 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-trial group)
Number of subjects: 668
Study 16822845 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 226
Study 16822845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 12624696 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron orally
Number of subjects: 150
Study 12624696 — intervention group
Group type: COMPARATOR
Intervention: 50 mg dolasetron orally plus 8 mg dexamethasone intravenously
Number of subjects: 150
Study 11400961 — intervention group
Group type: COMPARATOR
Intervention: Single sentinel node removed
Number of subjects: 1436
Study 11400961 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sentinel nodes removed
Number of subjects: 1436
Study 9230639 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (selective alpha2 antagonist)
Number of subjects: 33
Study 9230639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 9230639 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan
Number of subjects: 33
Study 8252951 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (10 mg/body square meters)
Number of subjects: 21
Study 8252951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 21
Study 3550340 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (bleomycin, Cytoxan, methotrexate, and 5-fluorouracil) in two cycles (one cycle if no tumor response) followed by standard treatment (combined irradiation and surgery or primary irradiation alone)
Number of subjects: 143
Study 3550340 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin and 5-fluorouracil) in three cycles prior to standard treatment
Number of subjects: 143
Study 3550340 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment without prior chemotherapy)
Number of subjects: 143
Study 3550340 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (induction chemotherapy)
Number of subjects: 143